POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 06/29/23

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Pro...

AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection Novel influenza drug targets identified faster and more cost-effectively using AI LONDON, UK / ACCESSWIRE / June 29, 2023 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the ...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to move into a new phase. Taking place over three years, the EncOVac Consortium...

Next Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding LONDON, UK / ACCESSWIRE / June 22, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases wi...

(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.

LONDON, UK / ACCESSWIRE / May 24, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Exe...

LONDON, UK / ACCESSWIRE / May 11, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces that at the Annual General Meeting held at 12:00pm today, al...

Annual Report & AGM Notice LONDON, UK / ACCESSWIRE / April 12, 2023 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company's Ann...

2023-03-30 09:27:53 ET Poolbeg Pharma press release ( OTCQB:POLBF ): FY Loss of £4.7M Cash balance of £16.2m at year end For further details see: Poolbeg Pharma reports FY results

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full year of operations with £16.2mln. Skillington describes it as a "very h...